{"id":725001,"date":"2023-01-23T09:07:55","date_gmt":"2023-01-23T14:07:55","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-elects-tina-s-nova-ph-d-as-executive-chair-of-the-board-of-directors\/"},"modified":"2023-01-23T09:07:55","modified_gmt":"2023-01-23T14:07:55","slug":"exagen-inc-elects-tina-s-nova-ph-d-as-executive-chair-of-the-board-of-directors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-elects-tina-s-nova-ph-d-as-executive-chair-of-the-board-of-directors\/","title":{"rendered":"Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors"},"content":{"rendered":"
\n

SAN DIEGO, Jan. 23, 2023 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN),\u00a0a leading provider of autoimmune testing solutions, announced today that Tina S. Nova, Ph.D. has been elected as Executive Chair of the Exagen Board of Directors, effective January 19, 2023. Dr. Nova succeeds Brian Birk, who has served as Chair of the Board of Directors at Exagen since 2018, and who will remain a member of the Board.\u00a0\u00a0<\/p>\n

Dr. Nova currently serves as President of Veracyte’s (Nasdaq: VCYT) U.S. CLIA business where she leads all aspects of the company\u2019s broad menu of diagnostic laboratory tests. She previously held the position of President & CEO of Decipher Biosciences until March 2021, when Veracyte purchased the organization for $600 million.\u00a0\u00a0 She has held numerous leadership roles in the life science industry, which include CEO of Molecular Stethoscope and SVP & General Manager of Oncology at Illumina.\u00a0\u00a0 Dr. Nova was the co-founder, President & CEO of Genoptix, which was purchased by Novartis AG for $470 million in 2011. She has also held senior positions with Nanogen, Inc., Ligand Pharmaceuticals, Inc. and Hybritech.<\/p>\n

\u201cI am excited to welcome Tina as Executive Chair at Exagen.\u00a0\u00a0Her broad experience with innovative healthcare companies and leadership in growing organizations with proprietary technology will be invaluable to Exagen as we look to expand our position as the premier provider of autoimmune testing solutions,\u201d said John Aballi, President and CEO of Exagen.\u00a0\u00a0\u201cI have had the pleasure of working with Tina for almost 15 years, and I\u2019m thrilled to work closely with her again as we continue to shape the future of Exagen.\u201d\u00a0\u00a0<\/p>\n

\u201cI am honored to have been elected Executive Chair and I\u2019m excited to take on this additional leadership role at Exagen,\u201d said Dr. Nova.\u00a0\u00a0 \u201cI also want to thank Brian Birk, who served as the company\u2019s Chair since 2018.\u00a0\u00a0Brian was instrumental in growing the organization into a leader in autoimmune testing and\u00a0I am pleased that he will remain a member of the Board.\u201d<\/p>\n

Dr. Nova currently serves on the Board of Azenta (Nasdaq: AZTA) and previously served on the Board of Directors of Veracyte and Arena Pharmaceuticals.\u00a0\u00a0Dr. Nova holds a Ph.D. in Biochemistry from the University of California, Riverside and a B.S. in Biological Sciences from the University of California, Irvine.<\/p>\n

\n About\u00a0Exagen<\/strong>\n <\/p>\n

Exagen\u00a0(Nasdaq: XGN) is a leading provider of autoimmune diagnostic, prognostic, and monitoring testing solutions.\u00a0Exagen\u00a0is a patient focused, discovery driven organization built on the success of AVISE testing and is investing in its product pipeline to support patients throughout their autoimmune diagnosis and treatment journeys. The goal at\u00a0Exagen\u00a0is to assist patients, physicians, and payors by enabling precision medicine.\u00a0Exagen\u00a0is located in\u00a0San Diego County\u00a0with clinical and research and development laboratories in\u00a0Vista, CA.<\/p>\n

For more information, please visit\u00a0Exagen.com<\/a>\u00a0and follow\u00a0@ExagenInc<\/a>\u00a0on Twitter.<\/p>\n

\n Forward-Looking Statements<\/strong>\n <\/p>\n

Exagen\u00a0cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Exagen\u2019s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding:\u00a0Exagen’s\u00a0goals and strategies; the potential utility and effectiveness of\u00a0Exagen’s\u00a0services and testing solutions that are currently available or in its development pipeline; the expected benefits of Dr. Nova\u2019s position with\u00a0Exagen; and\u00a0Exagen’s\u00a0potential growth and success and its ability to continue to grow and succeed. The inclusion of forward-looking statements should not be regarded as a representation by\u00a0Exagen\u00a0that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Exagen\u2019s business, including, without limitation: the COVID-19 pandemic may continue to adversely affect its business, financial condition and results of operations, including as a result of slowdown in its operations as well as those of its suppliers and courier services, impeding patient movement and interruptions to healthcare services causing a decrease in test volumes, disruptions to the supply chain of material needed for its tests causing an increase in cost per test, its sales and commercialization activities and its ability to receive specimens and perform or deliver the results from its tests, delays in reimbursement and coverage decisions from Medicare and third-party payors and in interactions with regulatory authorities, and delays in ongoing and planned clinical trials involving its tests; Exagen\u2019s commercial success depends upon attaining and maintaining significant market acceptance of its testing products and promoted therapeutics among rheumatologists, patients, third-party payors and others in the medical community; Exagen\u2019s ability to successfully execute on its business strategies; third-party payors not providing coverage and adequate reimbursement for Exagen\u2019s testing products or promoted therapeutics, including\u00a0Exagen’s\u00a0ability to collect funds due; Exagen\u2019s ability to obtain and maintain intellectual property protection for its testing products; regulatory developments affecting Exagen\u2019s business; and other risks described in Exagen\u2019s prior press releases and Exagen\u2019s filings with the\u00a0Securities and Exchange Commission\u00a0(“SEC”), including under the heading \u201cRisk Factors\u201d in Exagen\u2019s Annual Report on Form 10-K for the year ended\u00a0December 31, 2021\u00a0and any subsequent filings with the\u00a0SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and\u00a0Exagen\u00a0undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.<\/p>\n

\n Contacts:<\/strong><\/p>\n

Investors Relations<\/strong>
\n
Exagen Inc.
Ryan Douglas
rdouglas@exagen.com<\/a>\u00a0
760.560.1525<\/p>\n

\n Company<\/strong>
\n
Exagen Inc.
Kamal Adawi, Chief Financial Officer
kadawi@exagen.com<\/a>
760.477.5514<\/p>\n

\n
\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN DIEGO, Jan. 23, 2023 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN),\u00a0a leading provider of autoimmune testing solutions, announced today that Tina S. Nova, Ph.D. has been elected as Executive Chair of the Exagen Board of Directors, effective January 19, 2023. Dr. Nova succeeds Brian Birk, who has served as Chair of the Board of Directors at Exagen since 2018, and who will remain a member of the Board.\u00a0\u00a0 Dr. Nova currently serves as President of Veracyte’s (Nasdaq: VCYT) U.S. CLIA business where she leads all aspects of the company\u2019s broad menu of diagnostic laboratory tests. She previously held the position of President & CEO of Decipher Biosciences until March 2021, when Veracyte purchased the organization for $600 million.\u00a0\u00a0 She … <\/p>\n

Continue reading “Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-725001","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nExagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-elects-tina-s-nova-ph-d-as-executive-chair-of-the-board-of-directors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, Jan. 23, 2023 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN),\u00a0a leading provider of autoimmune testing solutions, announced today that Tina S. Nova, Ph.D. has been elected as Executive Chair of the Exagen Board of Directors, effective January 19, 2023. Dr. Nova succeeds Brian Birk, who has served as Chair of the Board of Directors at Exagen since 2018, and who will remain a member of the Board.\u00a0\u00a0 Dr. Nova currently serves as President of Veracyte’s (Nasdaq: VCYT) U.S. CLIA business where she leads all aspects of the company\u2019s broad menu of diagnostic laboratory tests. She previously held the position of President & CEO of Decipher Biosciences until March 2021, when Veracyte purchased the organization for $600 million.\u00a0\u00a0 She … Continue reading "Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-elects-tina-s-nova-ph-d-as-executive-chair-of-the-board-of-directors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-23T14:07:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNDEzMSM1MzY3ODY0IzIwMTA5NzI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-inc-elects-tina-s-nova-ph-d-as-executive-chair-of-the-board-of-directors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-inc-elects-tina-s-nova-ph-d-as-executive-chair-of-the-board-of-directors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors\",\"datePublished\":\"2023-01-23T14:07:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-inc-elects-tina-s-nova-ph-d-as-executive-chair-of-the-board-of-directors\\\/\"},\"wordCount\":963,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-inc-elects-tina-s-nova-ph-d-as-executive-chair-of-the-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczNDEzMSM1MzY3ODY0IzIwMTA5NzI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-inc-elects-tina-s-nova-ph-d-as-executive-chair-of-the-board-of-directors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-inc-elects-tina-s-nova-ph-d-as-executive-chair-of-the-board-of-directors\\\/\",\"name\":\"Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-inc-elects-tina-s-nova-ph-d-as-executive-chair-of-the-board-of-directors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-inc-elects-tina-s-nova-ph-d-as-executive-chair-of-the-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczNDEzMSM1MzY3ODY0IzIwMTA5NzI=\",\"datePublished\":\"2023-01-23T14:07:55+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-inc-elects-tina-s-nova-ph-d-as-executive-chair-of-the-board-of-directors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-inc-elects-tina-s-nova-ph-d-as-executive-chair-of-the-board-of-directors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-inc-elects-tina-s-nova-ph-d-as-executive-chair-of-the-board-of-directors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczNDEzMSM1MzY3ODY0IzIwMTA5NzI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczNDEzMSM1MzY3ODY0IzIwMTA5NzI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-inc-elects-tina-s-nova-ph-d-as-executive-chair-of-the-board-of-directors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-elects-tina-s-nova-ph-d-as-executive-chair-of-the-board-of-directors\/","og_locale":"en_US","og_type":"article","og_title":"Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors - Market Newsdesk","og_description":"SAN DIEGO, Jan. 23, 2023 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN),\u00a0a leading provider of autoimmune testing solutions, announced today that Tina S. Nova, Ph.D. has been elected as Executive Chair of the Exagen Board of Directors, effective January 19, 2023. Dr. Nova succeeds Brian Birk, who has served as Chair of the Board of Directors at Exagen since 2018, and who will remain a member of the Board.\u00a0\u00a0 Dr. Nova currently serves as President of Veracyte’s (Nasdaq: VCYT) U.S. CLIA business where she leads all aspects of the company\u2019s broad menu of diagnostic laboratory tests. She previously held the position of President & CEO of Decipher Biosciences until March 2021, when Veracyte purchased the organization for $600 million.\u00a0\u00a0 She … Continue reading \"Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-elects-tina-s-nova-ph-d-as-executive-chair-of-the-board-of-directors\/","og_site_name":"Market Newsdesk","article_published_time":"2023-01-23T14:07:55+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNDEzMSM1MzY3ODY0IzIwMTA5NzI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-elects-tina-s-nova-ph-d-as-executive-chair-of-the-board-of-directors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-elects-tina-s-nova-ph-d-as-executive-chair-of-the-board-of-directors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors","datePublished":"2023-01-23T14:07:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-elects-tina-s-nova-ph-d-as-executive-chair-of-the-board-of-directors\/"},"wordCount":963,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-elects-tina-s-nova-ph-d-as-executive-chair-of-the-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNDEzMSM1MzY3ODY0IzIwMTA5NzI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-elects-tina-s-nova-ph-d-as-executive-chair-of-the-board-of-directors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-elects-tina-s-nova-ph-d-as-executive-chair-of-the-board-of-directors\/","name":"Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-elects-tina-s-nova-ph-d-as-executive-chair-of-the-board-of-directors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-elects-tina-s-nova-ph-d-as-executive-chair-of-the-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNDEzMSM1MzY3ODY0IzIwMTA5NzI=","datePublished":"2023-01-23T14:07:55+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-elects-tina-s-nova-ph-d-as-executive-chair-of-the-board-of-directors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-elects-tina-s-nova-ph-d-as-executive-chair-of-the-board-of-directors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-elects-tina-s-nova-ph-d-as-executive-chair-of-the-board-of-directors\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNDEzMSM1MzY3ODY0IzIwMTA5NzI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNDEzMSM1MzY3ODY0IzIwMTA5NzI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-elects-tina-s-nova-ph-d-as-executive-chair-of-the-board-of-directors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/725001","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=725001"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/725001\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=725001"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=725001"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=725001"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}